Related Experiment Video

Updated: Jul 26, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.0K

Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine

Ann M Miller1, Steven M Varga1

  • 1Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.

Cell Reports. Medicine
|June 21, 2023
PubMed

Insights

A new maternal vaccine for respiratory syncytial virus (RSV) is safe and effective. It significantly reduced severe RSV lower respiratory tract infections in infants within six months of birth.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Respiratory Syncytial Virus (RSV) is a leading cause of severe lower respiratory tract infections in infants.
  • Maternal immunization is a promising strategy to protect infants from RSV during their first months of life.

Purpose of the Study:

  • To evaluate the safety and efficacy of a maternal bivalent RSV prefusion F vaccine.
  • To assess the vaccine's impact on reducing severe RSV-associated lower respiratory tract infections in infants.

Main Methods:

  • Phase 3 clinical trial involving maternal vaccination.
  • Follow-up of infants for severe RSV-associated lower respiratory tract infections at 90 and 180 days post-birth.

Main Results:

  • The maternal bivalent RSV prefusion F vaccine demonstrated a favorable safety profile.
  • Significant vaccine efficacy was observed in preventing severe RSV-associated lower respiratory tract infections in infants.

Conclusions:

  • Maternal immunization with the bivalent RSV prefusion F vaccine is a safe and effective approach.
  • This vaccination strategy offers substantial protection to infants against severe RSV disease.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.9K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
44.8K
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.6K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
366
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.2K